|
George M. Gill, MD, has more than 30 years of senior-level experience in clinical research and regulatory affairs, and has supported the advancement of more than 20 products - including 11 cancer products - through the regulatory approval process in the United States, Canada and Europe. Prior to joining Oncolytics, Dr. Gill held top positions with several major pharmaceutical companies including ICI Pharmaceuticals (now AstraZeneca), The Bristol-Myers Company (now Bristol-Myers Squibb) and Hoffman-La Roche. Dr. Gill holds a B.Sc. (chemistry) from Dickinson College in Pennsylvania and an MD from the School of Medicine at the University of Pennsylvania. | 